Metabolic dysfunction‐associated steatotic liver disease and sex‐specific risk of fatal and non‐fatal cardiovascular events: A meta‐analysis

Documenti analoghi

• Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
  di: Claudio Maffeis, et al.
  Pubblicazione: (2024)
• Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study
  di: Michela Vergani, et al.
  Pubblicazione: (2025)
• Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
  di: Yu Peng, et al.
  Pubblicazione: (2025)
• Ceramide‐based risk score CERT‐1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study
  di: Alessandro Mantovani, et al.
  Pubblicazione: (2024)
• Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
  di: Chloë Aernouts, et al.
  Pubblicazione: (2024)